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measured non-invasively with arterial spin
labelling
S Peter Johnson*,1,2,4, Rajiv Ramasawmy1,2,4, Adrienne E Campbell-Washburn2,3, Jack A Wells2,
Mathew Robson1, Vineeth Rajkumar1, Mark F Lythgoe2,5, R Barbara Pedley1,5 and Simon Walker-Samuel2,5
1UCL Cancer Institute, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E 6DD, UK; 2UCL
Centre for Advanced Biomedical Imaging, University College London, Paul O’Gorman Building, 72 Huntley Street, London WC1E
6DD, UK and 3Cardiovascular and Pulmonary Branch, Division of Intramural Research, National Heart, Lung and Blood Institute,
National Institutes of Health, Bethesda, MD 20892, USA
Background: Non-invasive measures of tumour vascular perfusion are desirable, in order to assess response to vascular targeting
(or modifying) therapies. In this study, hepatic arterial spin labelling (ASL) magnetic resonance imaging (MRI) was investigated to
measure acute changes in perfusion of colorectal cancer in the liver, in response to vascular disruption therapy with OXi4503.
Methods: SW1222 and LS174T tumours were established in the liver of MF1 nu/nu mice via intrasplenic injection. Perfusion and R2
*
MRI measurements were acquired with an Agilent 9.4T horizontal bore scanner, before and at 90min after 40mgkg 1 OXi4503.
Results: A significant decrease in SW1222 tumour perfusion was observed ( 43±33%, Po0.005). LS174T tumours had a
significantly lower baseline level of perfusion. Intrinsic susceptibility MRI showed a significant increase in R2
* in LS174T tumours
(28±25%, Po0.05). An association was found between the change in tumour perfusion and the proximity to large vessels, with
pre-treatment blood flow predictive of subsequent response. Histological evaluation confirmed the onset of necrosis and
evidence of heterogeneous response between tumour deposits.
Conclusions: Hepatic ASL-MRI can detect acute response to targeted tumour vascular disruption entirely non-invasively. Hepatic
ASL of liver tumours has potential for use in a clinical setting.
Angiogenesis is a key hallmark of cancer biology (Hanahan and
Weinberg, 2011), and while this enables the delivery of nutrients
and oxygen to meet the metabolic demands of the malignant cells,
it also provides a route through which to administer therapeutic
agents. Methods for measuring tumour vascular perfusion are
therefore in demand, both as research tools and as a means to
characterise and monitor tumours in patients. The development of
non-invasive measures of vascular perfusion in tumours is
particularly appropriate as the conventional radiological assess-
ment of response (using the RECIST criteria; Eisenhauer et al,
2009) evaluates changes in tumour size, which overlooks functional
changes that can occur over much shorter timescales and could be
equally indicative of a successful response to the therapy.
A number of magnetic resonance imaging (MRI) techniques
have been used to assess acute response to vascular targeted
therapy, including contrast-enhanced MRI (Patterson et al, 2012b),
intrinsic susceptibility (IS)-MRI (Robinson et al, 2005), vessel size
imaging (Burrell et al, 2012; Nielsen et al, 2012) and diffusion MRI
(Koh et al, 2009; Nathan et al, 2012). However, the baseline
perfusion of the tumour vasculature, and the acute (i.e., within
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several hours of administration) assessment of response to vascular
therapy could provide a better understanding of the tumour
vascular microenvironment and potentially predictive indicators of
drug action. Intrinsic susceptibility MRI has shown promise in the
acute setting, with some indication of prognostic value in pre-
therapy measurements (Robinson et al, 2005). The IS-MRI can be
used to quantify deoxyhaemoglobin build-up via assessment of the
transverse relaxation rate R2*; however, physiological interpreta-
tion of variations in such measurements can be challenging due to
its dependence on numerous physiological processes, such as
vascular geometry, paramagnetic cellular debris associated with
necrosis, and haemosiderin. A direct method for measurement of
tumour perfusion would therefore be an improvement on IS-MRI-
measured vascular haemodynamics.
We recently investigated the use of arterial spin labelling (ASL)
MRI to measure the combined arterial and portal venous perfusion
in both normal mouse liver and a mouse model of colorectal
metastasis to the liver (Ramasawmy et al, 2014). ASL uses the flow
of blood water to estimate perfusion in ml g 1min 1, and thus
does not require administration of a contrast agent, allowing for
repeated perfusion measurements without the need to wait for a
contrast agent to disperse. Perfusion can then be measured before
and immediately following drug administration. Moreover, hepatic
ASL offers good potential for translation onto human MRI
scanners and for use in the clinic in these deep-sited tumours,
particularly for patient populations that cannot be administered a
contrast agent, as it has been employed in other liver conditions
(Bokkers et al, 2012; Zou et al, 2014).
In the current study, we have continued our previous work by
investigating the utility of ASL in the assessment of acute response
to the second-generation combretastatin molecule OXi4503
(combretastatin A1 di-phosphate/CA1P), a potent vascular dis-
rupting agent, in a mouse model of colorectal metastasis to the
liver. Two human colorectal carcinoma cell lines were studied
(LS174T and SW1222), with well-characterised and markedly
different vascular characteristics (El et al, 2007). The aim of this
research was to evaluate whether ASL can provide a direct measure
of tumour perfusion for prognostic measurements both before and
at an acute time point after vascular targeted therapy. As the model
used created numerous metastatic tumours within the liver, a
secondary aim of the study was to investigate the relationship
between response to therapy and the location of tumour deposits
within the liver.
MATERIALS AND METHODS
Cell lines and tissue culture. The human colorectal carcinoma
cell lines SW1222 and LS174T (El et al, 2007) were cultured in
Dulbecco’s Modified Eagles Medium (PAA, GE Healthcare,
Fairfield, CT, USA) containing 5mM L-glutamine (PAA, GE
Healthcare) and 10% v/v Fetal bovine serum (Life Technologies,
Carlsbad, CA, USA). Cells were grown in a 37 1C humidified
incubator at 5% CO2.
In vivo model of liver metastasis. All animal studies were
approved by the University College London Biological Services
Ethical Review Committee and licensed under the UK Home
Office regulations and the Guidance for the Operation of Animals
(Scientific Procedures) Act 1986 (Home Office, London, UK) and
United Kingdom Co-ordinating Committee on Cancer Research
Guidelines for the Welfare and Use of Animals in Cancer Research
(Workman et al, 2010). To establish liver tumours (Fidarova et al,
2008), MF1 nu/nu mice (female, 6–8 weeks old, 25–30 g) were
anaesthetised with isoflurane in O2 at a concentration of 4% for
induction, followed by 1.5% for maintenance. A subcutaneous
injection of 0.1mg kg 1 buprenorphine (Vetergesic, Reckitt
Benckiser, UK) was administered and the flank of the animal
sterilised with clorhexidine solution. A laparotic incision of
approximately 1 cm was then made above the location of the
spleen and the organ exteriorised for injection. SW1222 (n¼ 6) or
LS174T (n¼ 6) cells were injected intrasplenically at a concentra-
tion of 1 106 cells in 100 ml of serum-free medium and allowed to
wash through to the liver for 5min, followed by splenectomy to
avoid the development of tumours at the site of injection. The
laparotic incision was sutured (Ethicon, Johnson & Johnson, New
Brunswick, NJ, USA) and closed with wound clips (Autoclip
system; Harvard Apparatus, Cambridge, UK).
Magnetic resonance imaging. All MRI was performed on a 9.4-T
Agilent VNMRS scanner (Agilent Technologies, Santa Clara, CA,
USA) with a 39-mm birdcage coil (RAPID Biomed, Rimpar,
Germany). Mice were anaesthetised with isoflurane in O2 at a
concentration of 4% for induction followed by 1–2% for
maintenance. Mice were then positioned in the centre of the bore
of the magnet, maintained at 37 1C with heated water pipes, and
monitored using respiratory bellows and a rectal temperature
probe (SA Instruments, Stony Brook, NY, USA).
Assessment of model development with morphological MRI. A
respiratory-gated, high-resolution, T2-weighted, fast spin echo
(FSE) sequence was used to determine tumour burden at 3, 4 and 5
weeks post implantation and later used to classify the location of
tumour deposits. Sequence parameters included: field of view
(FOV)¼ 35 35mm2, matrix size¼ 256 256, TR¼ 1500ms,
echo train length¼ 4, effective TE¼ 26ms, 40 0.5mm contig-
uous slices to cover the entire liver, and four averages.
Voxels corresponding to liver and tumour tissue, which
appeared hyper-intense relative to normal liver, were manually
segmented using Amira (Visualisation Sciences Group, Hillsboro,
OR, USA). Tumour locations were manually assessed on high-
resolution T2 weighted images and divided into three categories:
(a) peripheral, (b) near small, and (c) near large vessels. The limit
to the tumours’ proximity to major vasculature was defined as 3–4
voxels (0.5mm). Venous and arterial blood vessels appear hypo-
intense on the T2-weighted image and small vessels were
categorised by a cross-sectional area less than 0.1mm2 (approxi-
mately 7–8 voxels in diameter).
Functional assessment of liver tumour response to vascular
disruption. Assessment of vascular perfusion change within liver
tumours following therapy with the VDA OXi4503 was performed
at 5 weeks post surgery. All six SW1222 tumour-bearing mice were
dosed with 40mg kg 1 of OXi4503, with normal liver acting as an
inherent internal control in order to minimise animal usage and to
provide relevant indication of functional change within the
tumours. Only three out of six LS174T models developed distinct
liver tumours; therefore, only these were put forward for VDA
therapy, again using internal controls of normal-appearing liver
tissue. Based on results from these initial experiments, a further six
SW1222 models were set up as external standalone controls, five of
which produced liver metastases. These mice were set up and
imaged exactly as the treated experimental groups albeit dosed with
a saline sham dose instead of OXi4503.
A primed intravenous (i.v.) line was positioned in the tail for
administration of OXi4503. Following morphological scanning, an
axial slice through the liver was identified for ASL and IS-MRI
scans. Baseline perfusion and R2* measurements were performed
before administering 40mg kg 1 OXi4503 (4mgml 1 stock
solution injected at 10ml kg 1 of body weight) via the i.v. line.
R2* measurements were acquired dynamically up to 90min post
dose, and were followed by a second perfusion acquisition. The
time point of 90min was used as previous in-house experiments in
subcutaneous tumours showed R2* increases after OXi4503 dosing
within this time frame.
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Arterial spin labelling. Arterial spin labelling data were acquired
using a single-slice respiratory triggered, Look-Locker flow-
sensitive alternating inversion recovery (FAIR) with a segmented
gradient-echo readout (Campbell-Washburn et al, 2013). Sequence
parameters included: slice thickness¼ 1mm, FOV¼ 30 30mm,
matrix size¼ 128 128, echo time (TE)¼ 1.18ms, inversion time
spacing¼ 110ms, Look-Locker readout pulse spacing 2.3ms, flip
angle¼ 81. Sequence repetition time: 13 s, 50 inversion recovery
readouts, 4 lines per segmented acquisition. A 6-mm localised
selective inversion was followed by a global inversion, with the
whole scan lasting around 14min.
Total liver perfusion was quantified using methods previously
described (Ramasawmy et al, 2014); briefly, the data were
quantified with the Belle model (Belle et al, 1998), alongside an
intravascular capillary blood longitudinal relaxation time that had
been previously measured in the ventricular blood pool of the
mouse heart at 1.9 s (Campbell-Washburn et al, 2012). A blood-
tissue partition coefficient of 0.95ml g 1 was taken from
85Krypton gas-clearance measurements previously reported (Rice
et al, 1977), and this constant was used for both liver and tumour
regions. A three-parameter fit of the inversion recovery, corrected
for the Look-Locker signal saturation (Deichmann, 1992), was used
for longitudinal relaxation time (T1) quantification following
retrospective gating analysis.
Perfusion values were calculated in regions of interest (ROIs)
corresponding to either tumour or normal tissue in the single slice
acquired in the ASL acquisition. Mean perfusion values were
estimated in each ROI.
Intrinsic susceptibility MRI. Values of the transverse relaxation
rate (R2*) were estimated from a respiratory-gated multi-echo,
multi-slice gradient-echo sequence (MGEMS). Sequence para-
meters included: 8 echoes (TE1¼ 2ms, echo spacing¼ 2ms),
TR¼ 280ms, matrix size¼ 128 128, FOV¼ 30 30mm2, 15
slices, and slice thickness¼ 1mm. R2* was estimated using a
maximum likelihood approach that took into account the Rician
distribution of the data (Walker-Samuel et al, 2010). Regions of
interest corresponding to individual tumours were manually
defined on all slices within the liver, and the average R2* value
estimated in each tumour.
Wilcoxon tests were performed on metastases and internal
controls of normal-appearing liver, before and after in situ dose for
both perfusion and R2* measurements.
Histological assessment. Tumours were excised at 24h post VDA
administration for histological assessment. Animals were adminis-
tered 12.5mgkg 1 of the perfusion marker Hoechst 33342 i.v. 1 min
before culling. Livers were excised and snap frozen in isopentane/
liquid nitrogen, before sectioning on a cryostat at 10mm thickness.
Immunohistochemical (IHC) staining for the blood vessel marker
CD31 was performed before imaging on a fluorescence microscope
(AxioImager, Zeiss, Oberkochen, Germany). Haematoxylin and eosin
staining for basic cell morphology was performed and imaged on a
brightfield microscope (AxioSkop, Zeiss).
RESULTS
SW1222 vs LS174T perfusion measurements. Initial measure-
ments of perfusion and R2*, for both SW1222 and LS174T
metastases and normal surrounding liver tissue (at 5 weeks post
implantation), can be seen in Figure 1. Segmentation of the
metastases was performed based on T1,selective maps, as it was
observed that the tumour T1,selective was significantly greater
(Po0.0001, Kruskal–Wallis ANOVA) than that of the liver and
major vasculature for both cell lines: T1,liver 1.34±0.07 s
(mean±s.d., data combined from both cell lines), T1,Portal Vein
0.29±0.21 s (both cell lines), T1,SW122 2.15±0.11 s (n¼ 6), and
T1,LS174T 2.49±0.13 s (n¼ 3).
Perfusion measurements from these metastases showed a
significant difference (Po0.0001, Kruskal–Wallis ANOVA)
between the liver, SW1222 and LS174T metastases: Pliver
2.32±0.34ml g 1min 1 (mean±std), PSW1222 1.03±0.72ml g
 1
min 1, PLS174T 0.28±0.16ml g
 1min 1 (Figure 1A). This lower
level of perfusion in tumours, compared with normal liver, is
consistent with qualitative fluorescence microscopy imaging of
perfusion seen in Figure 1C and D, where the presence of the
perfusion marker Hoechst (blue) is lower in the tumour tissue (*)
for both SW1222 (Figure 1C) and LS174T (Figure 1D) compared
with normal surrounding liver parenchyma (arrow). Blood vessels,
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Figure 1. Baseline perfusion of tumour metastases. Average baseline estimates of blood perfusion from ASL (A) and R2* from IS-MRI (B) in normal-
appearing liver (n¼6), SW1222 tumours (n¼6) and LS174T tumours (n¼ 3) (** indicates Po0.01, *** indicates Po0.005, **** indicates Po0.001
significant differences). Fluorescence microscopy of blood vessels (CD31, red) and perfusion (Hoechst 33342, blue) in SW1222 tumours (C) and
LS174T tumours (D). Arrows indicate areas of normal liver tissue and stars indicate areas of tumour tissue.
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marked by CD31 in red, show a decreased abundance, penetration,
and organisation within tumour tissue compared with normal
liver.
A difference between SW1222 and LS174T tumours is also
observable, with fewer blood vessels and perfusion in the LS174T
tumours, further corroborating the obtained ASL measurements.
This may contribute to the observed difference in R2* (Figure 1B),
where LS174T tumours have a significantly slower value than
SW1222 tumours and normal liver. A significant difference
(Po0.0001, Kruskal–Wallis ANOVA) was measured between average
R2* estimates in normal-appearing liver, LS174T tumours and
SW1222 tumours: R2*liver¼ 148±010 s 1, R2*SW1222¼ 144±17 s 1,
and R2*LS174T¼ 47±4 s 1.
Functional response of the tumour vasculature to disruption
with OXi4503. Before OXi4503 delivery, tumours displayed
variable baseline measurements of perfusion and R2*, with a
heterogeneous spatial distribution for each parameter within each
tumour. Following treatment with OXi4503, a heterogeneous
response was observed in both tumour types by ASL and IS-MRI
techniques, as can be seen in the example maps shown in
Figure 2A. Absolute and relative changes from baseline in
perfusion and R2* measurements across groups are shown in
Table 1, with normal appearing liver from the same animals
included as an internal control; a significant decrease in perfusion
was detected in SW1222 metastases for both treated and saline
control groups. The decrease in perfusion of the saline control
group is not fully understood, though actual perfusion change is
small, it is potentially due to minor dehydration caused by
prolonged imaging (Ramasawmy et al, 2014). No significant
change was measured in treated LS174T tumours, probably due to
their low levels of baseline perfusion. Perfusion in normal-
appearing liver tissue was varied, although it decreased non-
significantly across the groups.
For change in R2* the only significant change measured was
within the VDA-treated LS174T tumours, with no significant
changes observed in the SW1222 tumours (treated and control) or
normal-appearing liver. Histological assessment of tumour metas-
tases viability by H&E staining shows that saline-dosed control
SW1222 tumours (Figure 2B) are highly nucleated and viable, with
little areas of necrosis, while both OXi4503-treated SW1222
(Figure 2C) and LS174T (Figure 2D) tumours have large central
necrosis with a small rim of surviving tumour cells surrounding the
metastasis. No change was observed in the surrounding normal
liver tissue.
Relationship between baseline and post-therapy parameter
estimates. Figure 3 displays the results of an analysis comparing
the change in perfusion and R2* values at 90min following
Oxi4503 administration, with values measured at baseline.
A significant, negative correlation (R2¼ 0.76, Po0.001 Pearson’s
R) was found between the change in tumour perfusion and the
value at baseline in SW1222 tumours (Figure 3A). However, no
corresponding correlation was observed between baseline R2* and
subsequent change in IS (P40.1, see Figure 3C). For LS174T
tumours, no significant correlation (P40.1) was measured
between the 90-min changes in perfusion and baseline perfusion
(Figure 3B), nor between baseline and 90min changes in R2*
(Figure 3D).
Relationship between response to OXi4503 and tumour loca-
tion. OXi4503-treated SW1222 tumours were categorised to
evaluate the effect of location within the liver and their subsequent
therapeutic response. Figure 4A shows a manually-segmented
three-dimensional rendering of a mouse liver from T2-weighted
MRI data, in which the liver parenchyma can be seen in semi-
transparent red, the major vasculature in purple. Tumours have
been coloured as classified by their proximity to large vessels
(48 voxels, red), small vessels (o8 voxels, green) and distal
(44 voxels, blue) to vasculature – typically located at the periphery
of the liver lobe (blue).
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Figure 2. Functional response of the tumour vasculature to disruption with OXi4503. Example high-resolution, axial images (A) with perfusion
(top row) and R2* (bottom row) maps overlaid on tumour ROIs (SW1222 on the left, and LS174T on the right, pre- and post OXi4503 therapy).
A heterogeneous spatial distribution can be seen in both parameters, both within individual tumour deposits and across different tumours
within the same liver. Histological staining by H&E is shown for saline control (B), and OXi4503-dosed SW1222 (C) and LS174T (D) tumours.
The arrows highlight the centre of liver tumour deposits (B, viable and C and D, necrotic).
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Figure 4B shows the change in perfusion (red, green and blue
outline) and R2* (solid red, green and blue) at 90min post OXi4503
when liver tumours were grouped according to their location (LV:
large vessels, SV: small vessels, and P: peripheral). Tumours close
to major vasculature were better perfused at baseline (Po0.05,
Kruskal–Wallis ANOVA): 1.5±0.8ml g 1min 1 (mean±stan-
dard deviation), 1.3±0.7ml g 1min 1, 0.6±0.3ml g 1min 1
for locations LV, SV, and P, respectively. No significant differences
in perfusion reduction were measured between the groups (P40.1,
Kruskal–Wallis ANOVA), though the data suggest that the largest
perfusion decreases can be observed in metastases proximal to
vasculature. The most consistent mean decrease in perfusion was
observed close to large vessels ( 62±19%, mean±standard
deviation), whereas a more varied decrease was seen in tumours
near smaller vessels ( 36±51%). Tumours in the periphery of the
liver lobe displayed a smaller but highly variable response in
perfusion ( 32±25%).
No significant differences (P40.05, Kruskal–Wallis ANOVA)
were measured between baseline R2* measurements, which were
110±50 s 1, 270±140ms 1, and 210±110 s 1 for locations LV,
SV, and P, respectively. No significant differences were measured
in R2* response post-OXi3403 as grouped by location (P40.15,
Kruskal–Wallis). Metastases in all locations behaved inconsistently
for R2* (large vessel 16±26% (mean±standard deviation), small
vessels  13±29%, and periphery  4±20%). Histological
assessment (Figure 4C), while not quantitative, provided some
evidence that tumour deposits located in close proximity could
have different responses to treatment, potentially moderated by
their distance from major blood vessels.
DISCUSSION
The aim of this study was to evaluate the response of a model of
liver metastasis to vascular disruption using hepatic ASL-MRI to
measure tumour perfusion, alongside IS-MRI as a measure of
deoxyhaemoglobin accumulation. This is a novel application of
ASL, demonstrating the first use of hepatic ASL-MRI to assess
response to vascular targeting therapy within the liver. The results
Table 1. Absolute and percentage changes (mean±s.d.) in perfusion and R2* for SW1222 metastases treated with OXi4503
(n¼6), LS174T metastases treated with OXi4503 (n¼3) and SW1222 metastases given saline control (n¼5)
SW1222þOXi4503 LS174TþOXi4503 SW1222þSaline
Perfusion
Tumours (ml g1min1) 0.49±0.44 0.04±0.23 0.17±0.31
%  43±33*** 61±152 16±39*
Liver (ml g 1min 1) 0.35±0.28 0.14±0.45 0.54±0.28
%  12±12  10±27 26±15
R2*
Tumours (s1) 5±28 13±12 11±16
% 0±26 28±25*** 6±10
Liver (s 1) 12±10 16±10 8±12
% 9±11 13±11 5±7
The internal control of the liver has been included for each group. Stars denote the significance determined by Wilcoxon tests (*Po0.05, **Po0.01, ***Po0.001).
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Figure 3. Correlation of baseline and post-OXi4503 measurements for perfusion (top row) and R2* (bottom row). Graphs show the change in the
value of each parameter in individual tumour deposits vs the baseline value. The change in perfusion measured in SW1222 tumours (A) displayed a
significant negative correlation with baseline measurements (R2¼0.76, Po0.001 Pearson’s R). Better-perfused tumours at baseline exhibited a
greater loss of perfusion following OXi4503 administration. LS174T tumour perfusion (B) was low at baseline, and no similar trend was found. For
both SW1222 (C) and LS174T (D) tumours, the R2* baseline data showed no correlation with baseline values.
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presented in this paper are consistent with previous research using
ultrasound imaging in subcutaneous tumours imaged before
OXi4503 treatment and 30min after (Mason et al, 2011), previous
acute studies of a different VDA (ZD6126) (Robinson et al, 2005),
the proposed vascular targeting action of the agent (Siemann,
2011), and relate well to ex vivo histological data from a similar
VDA (CA4P) used in SW1222 subcutaneous tumours (El-Emir
et al, 2005). The results are also consistent with other studies
investigating OXi4503 (CA1P) in particular, which has been shown
to significantly reduce tumour blood vessel perfusion within
30min of dosing with a 90% reduction observed at 4 h, albeit in a
subcutaneous setting of different tumour types (Salmon and
Siemann, 2006), using ex vivo histology and in vivo dynamic
contrast enhanced MRI. OXi4503 has also been used in an
intravital setting through use of a window chamber model of breast
cancer (Wankhede et al, 2010), showing tumour vascular structural
collapse from the earliest time-point imaged of 2 h.
The use of hepatic ASL in the present study allowed novel
insight into the dynamics of response to vascular disruption in an
orthotopic setting and exogenous contrast label free, based on
tumour pathophysiology and location within the liver. These
observations could potentially inform future prognostic markers of
response, and are discussed below.
Hepatic ASL is able to monitor differences in response to
vascular disruption. Given that the extent of vascularisation of
LS174T tumours is known to be low and much less extensive than
the SW1222 tumours (Kalber et al, 2008; Folarin et al, 2010), which
in turn are less well perfused than normal tissue (Figure 1), the
perfusion measured in these different tissues reflect this.
A significant reduction in perfusion was observed at 90min
following administration of OXi4503 in SW1222 tumours, while
perfusion changes in LS174T tumours were highly varied, due to
the low baseline values (Figure 2A; Table 1). A low initial level of
perfusion is a limitation of the ASL technique’s sensitivity, as
further decreases may be below the detection threshold of the
technique, though this would indicate that there was minimal
vasculature to target. A reduction in perfusion of SW1222 tumours
was also noted after saline control dose, albeit not as pronounced;
the physiological mechanism behind this change is not known;
however, it does highlight the sensitivity of the method used.
A significant change in R2* measurements was only observed in
post-treatment LS174T tumours, indicating that a build-up of
deoxyhaemoglobin and subsequent change in R2* may act as a
complimentary biomarker when tumour perfusion is minimal.
Histological assessment of tumour deposits showed viable tissue
for saline controls (Figure 2B), and centrally necrotic deposits for
OXi4503-treated SW1222 (Figure 2C) and LS174T (Figure 2D)
tumour tissue.
Relationship between baseline and post-OXi4503 perfusion
measurements. We observed that baseline perfusion in SW1222
tumour deposits was significantly correlated with the subsequent
decrease in perfusion at 90min following OXi4503 administration
(Figure 3). Such acute, non-invasive measurements of perfusion
changes are not generally possible, as the majority of other
approaches require a contrast agent to be administered (Lee et al,
2014), and disperse, before follow-up measurements can be taken.
One of the few examples of rapid tumour imaging of perfusion
without the need for extended periods of contrast agent dispersal is
the use of microbubbles in ultrasound, which are dispersed within
minutes following administration (Mason et al, 2011). Ultrasound
has also been shown to be capable of imaging vascular disruption
over a similar time course without contrast agent, through the use
of Colour-Doppler technique (Hadimani et al, 2013). However,
this was in a superficial subcutaneous tumour siting; in this study,
we have shown that ASL-MRI can correlate pre- and post-
treatment perfusion in tumour sited deeply within an organ.
Therefore, ASL-MRI could be a predictor of acute VDA efficacy,
with potential use as a diagnostic tool for patient stratification and
treatment planning. R2*, for example, has been used clinically to
assess response to OXi4503, though no acute response (o3 h) was
seen (Patterson et al, 2012a). The potential to highlight those
metastases that may respond positively to treatment vs those that
will not, based on baseline perfusion, could spare patients from
unnecessary treatment. Targeting of different tumour pathophy-
siologies often requires combination approaches to treatment for
adequate response, especially with regard to VDAs (Pedley et al,
2002), so knowledge obtained from a biomarker of tumour
perfusion could provide a deeper insight into the mechanics of
tumour response to therapy in vivo.
Robinson et al (2005) found baseline R2* to be predictive of
subsequent response, although this was evaluated in different cell
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Figure 4. The dependency of tumour location within the liver and the magnitude of perfusion changes. Analysis of SW1222 tumours following
dosing with OXi4503. (A) A three-dimensional visualisation of an example mouse liver at week 5 post implantation, showing liver parenchyma
(semi-transparent red), and major vasculature (purple). Tumours have been coloured according to their proximity to either a large vessel
(40.1mm2, red), small vessel (green) or no visible vessel (blue). (B) The percentage change in perfusion and R2* at 90min following administration
of 40mgkg 1 of OXi4503, categorised according to proximity to vessels and location within the liver. Large perfusion decreases were observed in
tumours close to either large (LV) or small (SV) blood vessels, although tumours near smaller vessels demonstrated a more variable response (as
evidenced by larger error bars). Tumours at the periphery (P) of the liver did not display a significant change in perfusion. No significant changes
were measured in R2* in any of the liver locations. (C) Example H&E slice of liver containing three different tumours located at a range of position to
a blood vessel, demonstrating a heterogeneous response to OXi4503 within the same liver.
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lines and using a different VDA, and in a different tumour model.
No equivalent result was found in this study, which could be due to
the difficulty in measuring R2* in liver, particularly as shimming of
the B0 field can be challenging due to susceptibility artefacts
propagating from surrounding lungs and gut, in addition to
respiratory and peristaltic motion artefacts which can be difficult to
control.
Heterogeneity of response to therapy based on tumour location.
Vascular disrupting agents are often said to be more effective
against larger tumours (Landuyt et al, 2000; Liu et al, 2015);
however, in this study we found no obvious dependence of change
in perfusion based on size. Certain tumour deposits, however,
based on histological assessment, were not affected by OXi4503 at
24 h post treatment (Figure 4C). As this was an unexpected result,
it was not possible to retrospectively link affected tumours to
perfusion measurements. The noted heterogeneity could be a
function of the time course of tumour necrosis, with those tumour
deposits that had not initially responded proceeding to do so at a
later point in time.
However, a potential factor influencing heterogeneous response
to OXi4503 treatment is the location of the tumour deposits within
the liver. The pharmacokinetics of drug delivery to the tumours
might be affected by systemic perfusion within the liver. By
categorising location within the liver relative to major blood
vessels, in an attempt to account for different degrees of perfusion,
we found that the reduction in perfusion was greatest and most
consistent in metastases close to large vessels (measured to have a
high level of baseline perfusion), similar but less consistent in
metastases close to smaller vessels (considered to have a medium
level of baseline perfusion), and was smallest in those at the
periphery of the liver (considered to be the least perfused tumours)
(Figure 4B).
Although we were unable to use histology data to directly link
this reduction in perfusion to direct action of vascular disruption, it
is still indicative of differential responses of metastases to the VDA,
as also demonstrated by the range of efficacy seen in neighbouring
tumour deposits by IHC (Figure 4C). This suggests that the
pharmacokinetics of drug action may be influenced by micro-
environmental factors such as tumour perfusion. This range of
responses between metastases dependent upon location and extent
of growth has been previously observed with the use of
radiolabelled antibodies (Siemann, 2011), which lends support to
our observations.
A limitation of this study was the use of a single-slice ASL
acquisition sequence. This permitted only partial coverage of the
liver; and hence, a number of metastases were omitted from
analysis; longitudinal measurements were also difficult as the
replication of exact image slice positions between sessions was
challenging. Since completion of this study, a multi-slice adaption
of the Look-Locker FAIR ASL sequence has been developed
(Campbell-Washburn et al, 2013). Utilising the vessel-selective
pseudo-continuous ASL sequences (Dai et al, 2008) could provide
a direct method for separating the arterial and venous contribu-
tions to the liver blood supply, from which response biomarkers
such as the hepatic perfusion index, a measure of the relative
contribution of the two supplies in individual metastases, could be
evaluated to further probe tumour pathophysiology (Cuenod et al,
2001; Schalkx et al, 2014).
CONCLUSION
This study has demonstrated the use of hepatic ASL-MRI to detect
acute response to the VDA OXi4503 in a mouse model of
colorectal carcinoma metastasis to the liver. Significant decreases in
SW1222 tumour (but not normal liver) perfusion were observed at
90min following administration, and baseline perfusion measure-
ments were found to be predictive of subsequent response.
Moreover, response to the drug was heterogeneous between
tumour deposits, with the siting of tumour deposits in the liver
relative to major vessels found to have a role. Given the ability of
hepatic ASL to measure acute changes in liver perfusion entirely
noninvasively, it has the potential to be used in a therapeutic
clinical setting.
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